Nassima Ait‐Daoud Tiouririne

Nassima Ait‐Daoud Tiouririne

Auto-generated profile, based on publicly available information

Nassima Ait‐Daoud Tiouririne

Department of Psychiatry and Neurobehavioral Sciences, Center for Leading Edge Addiction Research (CLEAR) University of Virginia School of Medicine 1215 Lee St Charlottesville Virginia USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in JMIR Formative Research
Verified
Journal Article
Open access
MWMarika Elise Waselewski
Marika Elise Waselewski
TFTabor Elisabeth Flickinger
Tabor Elisabeth Flickinger
CCChelsea Canan
Chelsea Canan
WHWilliam Harrington
William Harrington
TFTaylor Franklin
Taylor Franklin
RDRebecca Anne Dillingham
Rebecca Anne Dillingham
Background: Opioid use disorder (OUD) is a public health crisis with more than 2 million people living with OUD in the United States. Medication-assisted treatment (MAT) is an evidence-based approach for the treatment of OUD that relies on a combination of behavioral therapy and medication. Less than half of those living with OUD are accessing this treatment. Mobile technology can enhance the treatment of chronic diseases in readily accessible and cost-effective ways through self-monitoring and support. Objective: The aim of this study is to describe the adaptation of a mobile platform for patients undergoing treatment for OUD and preliminary pilot testing results. Methods: Our study was conducted with patient and provider participants at the University of Virginia MAT clinic and was approved by the institutional review board. The formative phase included semistructured interviews to understand the needs of patients with OUD, providers’ perspectives, and opportunities for MAT support via a mobile app. A second round of formative interviews used mock-ups of app features to collect feedback on feature function and desirability. Formative participants’ input from 16 interviews then informed the development of a functional smartphone app. Patient participants (n=25) and provider participants (n=3) were enrolled in a 6-month pilot study of the completed platform. Patient app use and usability interviews, including a system usability score and open-ended questions, were completed 1 month into the pilot study. Open-ended responses were analyzed for prevalent themes. Results: Formative interviews resulted in the development of a mobile app, named HOPE, which includes both evidence-based and participant-suggested features. The features included daily prompts for monitoring mood, stress, treatment adherence, and substance use; patient tracking of goals, reminders, and triggering or encouraging experiences; informational resources; an anonymous community board to share support with other patients; and secure messaging for communication between patients and providers. All patient participants engaged with at least one app feature during their first month of pilot study participation, and the daily self-monitoring prompts were the most used. Patients and providers reported high levels of system usability (mean 86.9, SD 10.2 and mean 83.3, SD 12.8, respectively). Qualitative analysis of open-ended usability questions highlighted the value of self-monitoring, access to support through the app, and perceived improvement in connection to care and communication for both patient and provider participants. Conclusions: The use of the HOPE program by pilot participants, high usability scoring, and positive perceptions from 1-month interviews indicate successful program development. By engaging with end users and eliciting feedback throughout the development process, we were able to create an app and a web portal that was highly usable and acceptable to study participants. Further work is needed to understand the program’s effect on clinical outcomes, patient linkage, and engagement in care.

24 September 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
DBDerek Blevins
Derek Blevins
CSChamindi Seneviratne
Chamindi Seneviratne
XWXin-Qun Wang
Xin-Qun Wang
BJBankole A. Johnson
Bankole A. Johnson
NANassima Ait-Daoud
Nassima Ait-Daoud

15 July 2026 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
NTNassima Ait‐Daoud Tiouririne
Nassima Ait‐Daoud Tiouririne
JLJospeh A. Legan
Jospeh A. Legan
EDEric Devine
Eric Devine
KLKristen Lee
Kristen Lee
EWElise M. Weerts
Elise M. Weerts
CSCharles Scott
Charles Scott
Background: The neuropeptide oxytocin offers a potentially effective treatment for alcohol use disorder (AUD). Acting centrally in the brain, oxytocin mediates a range of behavioral effects, including reward, stress response, social affiliation, learning, memory, and addictive behaviors. Animal studies demonstrate oxytocin's ability to reduce alcohol consumption, but results in human trials have been mixed. Some studies report reductions in withdrawal symptoms, heavy drinking, and craving, whereas others show no effects. The purpose of this 12‐week clinical trial was to evaluate the efficacy and safety of intranasal oxytocin in individuals with AUD. Methods: Oxytocin (up to 70 International Units [IU]/day) or placebo was administered to 100 individuals diagnosed with AUD in a double‐blind, randomized, 12‐week multisite trial. The primary outcome was the weekly percentage of heavy drinking days (PHDD) over 10 weeks of maintenance treatment. Secondary outcomes included additional drinking measures, urge to drink, psychological assessments, alcohol‐related consequences, nicotine use, and safety and tolerability of intranasal oxytocin. Results: No significant differences were observed in PHDD between groups during the 10‐week maintenance phase. However, a small, numerically greater reduction in drinking was seen in the oxytocin group compared with placebo from weeks 9 to 12. Similar patterns were found across secondary drinking outcomes. No significant differences were observed in AUD symptoms, alcohol‐related consequences, craving, mood, sleep, pain, or substance use. At the end of treatment, participants receiving oxytocin scored significantly lower on measures of anger and physical aggression. Oxytocin was well tolerated; adverse events were mild and comparable across groups. The most common event in both groups was hyposmia. Conclusion: Intranasal oxytocin was well tolerated but did not significantly reduce drinking or AUD‐related outcomes. Higher doses, longer treatment duration, or larger trials may be required to identify responsive subgroups and determine oxytocin's efficacy in AUD. Trial Registration: ClinicalTrials.gov , Identifier: NCT03878316. Registered March 14, 2019 ( https://clinicaltrials.gov/ct2/show/NCT03878316 )

28 May 2026 in Biological Psychiatry
Verified
Journal Article
Closed access
JIJames J. Mahoney Iii
James J. Mahoney Iii
DTDaisy G.Y. Thompson-Lake
Daisy G.Y. Thompson-Lake
LJLucas Johnson
Lucas Johnson
NANassima Ait-Daoud
Nassima Ait-Daoud
WLWendy J. Lynch
Wendy J. Lynch
ARAli Rezai
Ali Rezai

12 November 2025 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
JRJason D Robinson
Jason D Robinson
RARobert M. Anthenelli
Robert M. Anthenelli
PCPaul M. Cinciripini
Paul M. Cinciripini
MKMaher Karam‐Hage
Maher Karam‐Hage
YCYong Cui
Yong Cui
NTNassima Ait‐Daoud Tiouririne
Nassima Ait‐Daoud Tiouririne
Background: Tobacco use disorder (TUD) and alcohol use disorder (AUD) frequently co‐occur and together are associated with worse prognoses. There are few options for treating both disorders concurrently. This study examined whether the antiepileptic drug topiramate would be effective for treating adults with both AUD and TUD. Methods: Participants ( n = 236) from three sites were randomly assigned to receive treatment adherence counseling and either placebo, low‐dose topiramate (up to 125 mg/day), or high‐dose topiramate (up to 250 mg/day) for up to 18 weeks, with a 5‐week titration period. The primary outcomes were the mean percentage of heavy drinking days (PHDD) and the smoking continuous abstinence rate with biochemical verification during the last 4 weeks of treatment. Secondary outcomes included quality of life and craving for alcohol and cigarettes. We also conducted post hoc exploratory repeated measures analyses to maximize the use of available data. Results: None of the prespecified primary or secondary outcomes differed across medication groups. However, the exploratory analyses indicated that participants treated with the 250 mg dose had lower mean PHDD and drinks per day than those taking the lower dose or placebo. Additionally, participants in both the 125 and 250 mg groups smoked fewer cigarettes per day and reported greater cigarette abstinence than those in the placebo group. Conclusions: While the primary analyses did not find evidence that topiramate decreases drinking and smoking behavior, likely influenced by a high attrition rate and poor medication adherence, exploratory repeated measures analyses suggest that topiramate 250 mg reduces drinking behavior and that both the 125 mg and 250 mg doses reduce smoking behavior. Future studies that maximize treatment adherence are needed to more definitively determine whether topiramate is an effective treatment for AUD and TUD.

27 October 2026 in The American Journal on Addictions
Verified
Journal Article
Open access
TTTheodore Tsonis
Theodore Tsonis
NTNassima Ait‐Daoud Tiouririne
Nassima Ait‐Daoud Tiouririne
NCNathan P. Charlton
Nathan P. Charlton
AMAvery Michienzi
Avery Michienzi
Background and Objectives: Chronic nitrous oxide (N 2 O) misuse causes heterogeneous neuropsychiatric toxicity. Methods: We retrospectively reviewed three middle‐aged adults with chronic N 2 O misuse and neuropsychiatric presentations. Results: Presentations included cognitive impairment, hallucinations, and variable neurologic dysfunction. Homocysteine was markedly elevated in all patients, while vitamin B12, methylmalonic acid, hematologic indices, and longitudinal outcomes varied. Discussion and Conclusions: These cases illustrate heterogeneous biochemical and clinical trajectories, with biochemical abnormalities not consistently corresponding to clinical severity or recovery. Scientific Significance: Clinicians should specifically assess N 2 O exposure in unexplained neuropsychiatric presentations and interpret cobalamin‐related biomarkers in clinical context.